Is There a Smart Path to Regulating Laboratory Developed Tests?
Xifin’s CEO sees a window of opportunity for lawmakers to modify the Final Rule on LDTs that will be a win-win for the industry and patients.
Xifin’s CEO sees a window of opportunity for lawmakers to modify the Final Rule on LDTs that will be a win-win for the industry and patients.
Xifin has added two major payors to its Payor Rate Transparency Monitor. Labs will now have even more data to help with reimbursements.
In 2023, digital health tech companies raised $10.7 billion, but patient satisfaction with healthcare quality declined.
COLA appointed Lynn Jeffers to its board of directors, bringing her extensive leadership experience in healthcare to support COLA.
The FDA’s new LDT rule could severely limit access to vital diagnostics, particularly in rural and marginalized communities, ADLM says.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
Beckman Coulter Life Sciences appointed Joe Fox as its new president, who will bring extensive leadership experience to the company.
The European consortium Solve-RD provided genetic diagnoses for rare disease patients, highlighting the power of international collaboration.